← All countries · Eastern Mediterranean
99%
MCV1
2025 · WHO/UNICEF estimate
95%
DTP3
2025 · WHO/UNICEF estimate
96%
IPV complete
2025 · WHO/UNICEF estimate
95%
HepB3
2025 · WHO/UNICEF estimate
2
Measles cases
2025 reported
15
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 99%2025 · WHO/UNICEF estimate | 99.4% | B · good | |
| DTP1First dose of diphtheria-tetanus-pertussis | 99%2025 · WHO/UNICEF estimate | 99.3% | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 95%2025 · WHO/UNICEF estimate | 95.0% | B · good | |
| IPV1First dose of inactivated polio vaccine | 99%2025 · WHO/UNICEF estimate | 99.0% | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 96%2025 · WHO/UNICEF estimate | 95.8% | D · poor | |
| MCV1First dose of measles-containing vaccine | 99%2025 · WHO/UNICEF estimate | 99.5% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 98%2025 · WHO/UNICEF estimate | 97.7% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 99%2025 · WHO/UNICEF estimate | 99.5% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 95%2025 · WHO/UNICEF estimate | 95.0% | B · good | |
| HepB birthHepatitis B birth dose within 24 hours | 86%2025 · WHO/UNICEF estimate | 86.3% | B · good | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 95%2025 · WHO/UNICEF estimate | 95.0% | B · good | |
| PCV1Pneumococcal conjugate vaccine, first dose | 98.4%2025 · Administrative (country-reported) | 98.4% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 95%2025 · WHO/UNICEF estimate | 95.1% | B · good | |
| RotaCRotavirus vaccine, complete series | 83%2025 · WHO/UNICEF estimate | 83.5% | B · good | |
| Yellow feverYellow fever vaccine (countries at risk) | 0%2017 · Administrative (country-reported) | 0% | too few points | D · poor |
| MenAMeningococcal A conjugate (meningitis belt) | 0%2017 · Administrative (country-reported) | 0% | too few points | D · poor |
| JEJapanese encephalitis vaccine (countries at risk) | 0%2017 · Administrative (country-reported) | 0% | too few points | D · poor |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 99%2024 · WHO/UNICEF estimate | — | D · poor | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | —% · Administrative (country-reported) | — | too few points | no data |
| HPV complete, girlsHPV programme coverage, complete series, girls | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, boysHPV programme coverage, first dose, boys | —% · Administrative (country-reported) | — | too few points | no data |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 22025 | 0.4per 1,000,000 total population | B · good | |
| Rubella all countries · vaccine evidence | 22025 | 0.4per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | D · poor | |
| Mumps all countries · vaccine evidence | 712025 | 14.1per 1,000,000 total population | C · weak | |
| Pertussis (whooping cough) all countries · vaccine evidence | 152025 | 3per 1,000,000 total population | C · weak | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | D · poor | |
| Tetanus (total) all countries · vaccine evidence | 22025 | 0.4per 1,000,000 total population | C · weak | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | D · poor | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Invasive meningococcal disease all countries · vaccine evidence | 202025 | 4per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 172025 | 3.4per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (76 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | M3 | General/routine | |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions, other groups | |
| DTAPDTaP (acellular) vaccine | 5 | Y3.6 | General/routine | This vaccine has replaced DTwP ( Whole cell) vaccine since mid 2025. |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2 | General/routine | The pentavalent whole cell vaccine has been replaced by the hexavalent acellular vaccine since mid 2025 for all doses |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M4 | General/routine | The pentavalent whole cell vaccine has been replaced by the hexavalent acellular vaccine since mid 2025 for all doses |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M6 | General/routine | The pentavalent whole cell vaccine has been replaced by the hexavalent acellular vaccine since mid 2025 for all doses |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 4 | M18 | General/routine | The pentavalent whole cell vaccine has been replaced by the hexavalent acellular vaccine since mid 2025 for all doses |
| DTWPDTwP (Whole cell) vaccine | 5 | Y3.6 | General/routine | this vaccine has been replaced by DTaP-Hib-HepB-IPV vaccine in mid 2025 |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | M2 | General/routine | The pentavalent whole cell vaccine has been replaced by the hexavalent acellular vaccine since mid 2025 for all doses |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | M4 | General/routine | The pentavalent whole cell vaccine has been replaced by the hexavalent acellular vaccine since mid 2025 for all doses |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | M6 | General/routine | The pentavalent whole cell vaccine has been replaced by the hexavalent acellular vaccine since mid 2025 for all doses |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 4 | M18 | General/routine | The pentavalent whole cell vaccine has been replaced by the hexavalent acellular vaccine since mid 2025 for all doses |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Adults | health care personnel, travelers to high risk areas and food handler personnel | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Health workers | health care personnel, travelers to high risk areas and food handler personnel | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Risk group(s) | health care personnel, travelers to high risk areas and food handler personnel | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Adults · SUBNATIONAL | health care personnel and offered during pre-marital screening (after titer check) | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Health workers · SUBNATIONAL | health care personnel and offered during pre-marital screening (after titer check) | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y9-Y45 | Adults | Target group: Y9-Y15 males & females (Eligible age group is 9-45 years males and females) |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y9-Y15 | HPV administered to females and males | Target group: Y9-Y15 males & females (Eligible age group is 9-45 years males and females) |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons 65Y and above |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | M2 | General/routine | The IPV vaccine has been included as part of the hexavalent vaccine since mid 2025 for all routine childhood doses |
| IPVIPV (Inactivated polio vaccine) | 2 | M4 | General/routine | The IPV vaccine has been included as part of the hexavalent vaccine since mid 2025 for all routine childhood doses |
| IPVIPV (Inactivated polio vaccine) | 3 | M6 | General/routine | The IPV vaccine has been included as part of the hexavalent vaccine since mid 2025 for all routine childhood doses |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Y1 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Risk group(s) · SUBNATIONAL | The vaccine is offered for travelers to high risk areas, pilgrims prior to Hajj and Umrah, Unvaccinated expatriates prior to obtaining residency. | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Y1 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Health workers | The vaccine is also offered to the following groups: Scholarship Students, Healthcare workers, Nursery workers, unvaccinated expatriates prior to obtaining residency. | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Risk group(s) | The vaccine is also offered to the following groups: Scholarship Students, Healthcare workers, Nursery workers, unvaccinated expatriates prior to obtaining residency. | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y2 | General/routine | The 2nd dose which is taken at 2 years is given within the combined MMRV vaccine (Since mid 2025) |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 2 | >=Y2 | General/routine | The 2nd dose which is taken at 2 years is given within the combined MMRV vaccine (Since mid 2025) |
| MPOXMpox (monkeypox) vaccine | 1 | Risk group(s) · SUBNATIONAL | Adult high risk group + post-exposure prophylaxis | |
| OPVOPV (Oral polio vaccine) | 1 | M12 | General/routine | |
| OPVOPV (Oral polio vaccine) | 2 | M18 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M2 | General/routine | The PCV20 vaccine has replaced the PCV13 vaccine since mid 2025 |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M4 | General/routine | The PCV20 vaccine has replaced the PCV13 vaccine since mid 2025 |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M6 | General/routine | The PCV20 vaccine has replaced the PCV13 vaccine since mid 2025 |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 4 | M18 | General/routine | The PCV20 vaccine has replaced the PCV13 vaccine since mid 2025 |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | M2 | General/routine | PCV-20 was introduced to 2025 immunization schedule in last few months in 2025 instead of PCV-13 |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | Risk group(s) | pilgrims, high risk groups, a person who planned for travelling Umra | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | Travellers | pilgrims, high risk groups, a person who planned for travelling Umra | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 2 | M4 | General/routine | PCV-20 was introduced to 2025 immunization schedule in last few months in 2025 instead of PCV-13 |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 3 | M6 | General/routine | PCV-20 was introduced to 2025 immunization schedule in last few months in 2025 instead of PCV-13 |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 4 | M18 | General/routine | PCV-20 was introduced to 2025 immunization schedule in last few months in 2025 instead of PCV-13 |
| RABIESRabies vaccine | 1 | Risk group(s) · SUBNATIONAL | Post exposure prophylaxis + pre-exposure prophylaxis for individuals at high risk of exposure | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | M4 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | M6 | General/routine | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | >=Y75 | Adults · SUBNATIONAL | For pregnant females during 23-26 gestational week. Also for adults aged 75 years and over and high risk adults aged 50 to <75 years. |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Pregnant women · SUBNATIONAL | For pregnant females during 23-26 gestational week. Also for adults aged 75 years and over and high risk adults aged 50 to <75 years. | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | >=Y50 | Risk group(s) · SUBNATIONAL | For pregnant females during 23-26 gestational week. Also for adults aged 75 years and over and high risk adults aged 50 to <75 years. |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Adults | For pregnant women & adolescent and adult | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | For pregnant women & adolescent and adult | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | Y10-Y12 | General/routine | Td(Tetanus toxoid and diphtheria for older children and adult ) vaccine was replaced by Tdap vaccine in 2025 immunization schedule for school children at 10-12 y & 16-18y for both males and females children. In addition the vaccine is offer to pregnant women. |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 7 | Y16-Y18 | General/routine | Td(Tetanus toxoid and diphtheria for older children and adult ) vaccine was replaced by Tdap vaccine in 2025 immunization schedule for school children at 10-12 y & 16-18y for both males and females children. In addition the vaccine is offer to pregnant women. |
| TTTT (Tetanus toxoid) vaccine | 1 | Health workers · SUBNATIONAL | people exposed to accidents, healthcare workers, pregnant women | |
| TTTT (Tetanus toxoid) vaccine | 1 | Pregnant women · SUBNATIONAL | people exposed to accidents, healthcare workers, pregnant women | |
| TTTT (Tetanus toxoid) vaccine | 1 | Risk group(s) · SUBNATIONAL | people exposed to accidents, healthcare workers, pregnant women | |
| TYPHOID_PSTyphoid polysaccharide vaccine | 1 | Risk group(s) · SUBNATIONAL | food handler personnel and travelers to high risk areas | |
| TYPHOID_PSTyphoid polysaccharide vaccine | 1 | Travellers · SUBNATIONAL | food handler personnel and travelers to high risk areas | |
| VARICELLAVaricella vaccine | 1 | Y1 | General/routine | |
| VARICELLAVaricella vaccine | 1 | Health workers | HCWs, Nursery workers | |
| VARICELLAVaricella vaccine | 1 | Risk group(s) | HCWs, Nursery workers | |
| VARICELLAVaricella vaccine | 2 | Y2 | General/routine | The 2nd dose which is taken at 2 years is given within the combined MMRV vaccine (Since mid 2025) |
| YFYF (Yellow fever) vaccine | 1 | Travellers · SUBNATIONAL | travellers to at risk areas | |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | Adults · SUBNATIONAL | For adult and high risk group | |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | Risk group(s) · SUBNATIONAL | For adult and high risk group |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.